[ HARMONIZER — NOT A MARKET ]
Home of the European Pharmacopoeia, which is legally binding in signatory states — the case where a harmonizer output binds directly rather than by national adoption.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
EUROPE
The Convention on the Elaboration of a European Pharmacopoeia, opened for signature on 22 July 1964 — an international treaty, which makes this the one entry on the harmonizer side of the axis whose output is genuinely binding rather than recommended. The Contracting Parties, now more than thirty European states together with the European Union, undertake to give the European Pharmacopoeia legal force in their territories. The Ph. Eur. is elaborated and published by the European Directorate for the Quality of Medicines & HealthCare, the Council of Europe body created under that Convention.
Directly, once a monograph is in force in a signatory state: the Ph. Eur. is the legally binding reference for the quality control of medicines and their ingredients, and a substance covered by a monograph must comply with it. This is the sharpest contrast on the whole axis — the United States Pharmacopeia acquires legal force through the FD&C Act and state adoption, whereas the Ph. Eur. acquires it through a treaty obligation the state itself signed. EDQM also operates the certification procedure that issues a Certificate of Suitability, the CEP.
WHAT TRANSFERS
The monograph transfers across every Contracting Party without renegotiation, which is the point of the treaty. The CEP transfers as evidence: it confirms that a substance’s quality is suitably controlled by the relevant monograph, supplemented where necessary, and can be submitted in place of the corresponding dossier detail to authorities that accept it — sparing the manufacturer from disclosing that detail to each applicant. What does not transfer is compliance with any other pharmacopoeia: meeting Ph. Eur. does not establish USP or JP compliance, and where a monograph differs between them the difference is real.
They are separate organisations with different memberships, and the Convention has Contracting Parties outside the EU. A substance can be subject to the Ph. Eur. in a state that is not an EU Member State, which is why treating this as an EU instrument produces the wrong scope.
It certifies that the monograph, supplemented as necessary, suitably controls the quality of the substance as made by a named manufacturer at a named site by a described route. It is not a GMP certificate and not a manufacturing authorisation, and it does not survive an unnotified change to the route.
Compliance is with the monograph in force, not with the edition a specification was written against. A specification frozen at an older supplement can be fully self-consistent and still out of compliance, which is a different failure from being wrong.
The general chapters and general monographs apply wherever a specific monograph refers to them, so an obligation can sit two references away from the substance being tested. Reading only the substance monograph reliably understates what applies.
The Convention on the Elaboration of a European Pharmacopoeia, opened for signature on 22 July 1964. Its Contracting Parties — more than thirty European states plus the European Union — undertake to give the Ph. Eur. legal force in their territories, so compliance is a treaty-derived legal obligation rather than a voluntary standard.
By mechanism. The Ph. Eur. binds because signatory states committed to it by treaty. USP standards acquire force in the United States through the Federal Food, Drug, and Cosmetic Act and, for practice chapters, through adoption by reference in state law. USP itself enforces nothing.
A CEP, issued by EDQM, confirming that the quality of a substance is suitably controlled by the relevant European Pharmacopoeia monograph, supplemented by additional requirements where necessary. It can be submitted to authorities that accept it in place of the corresponding dossier detail. It is not a GMP certificate and it is tied to the manufacturing route it was granted for.
No. It is elaborated and published by EDQM, a body of the Council of Europe, under a 1964 Council of Europe treaty. The European Union is one of the Contracting Parties, but so are European states outside the EU — so the Ph. Eur. applies across a wider territory than EU law does.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Council of Europe: requirements still arrive through the authorities that adopt this body’s output, and the edition in force is theirs to state.
SPEQ records no harmonizer participation for Council of Europe. Requirements here are set by the authorities above rather than arriving through a harmonized guide, so evidence prepared for another market does not transfer on that basis.